TITLE

Phase II

PUB. DATE
July 2005
SOURCE
Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p16
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Provides information related to latest phase II clinical trials. Extension of trial enrollment for Centocor Inc.'s CNTO 1275 for Crohn's disease; Initiation of a trial for OncoVEX, drug developed by BioVEX Ltd. for malignant melanoma tumors; Completion of a trial of SPRC-AB01 for chronic rhinosinusitis by Naryx Pharma.
ACCESSION #
17590390

 

Related Articles

  • Crohn's Disease: MMF Not the Cure-All for 6-MP/AZA Treatment Failures. Young, R. L.; Thompson, Jon S. // American Journal of Gastroenterology;Jul2000, Vol. 95 Issue 7, p1626 

    Discusses research being done on the efficacy of mycophenolate mofetil (MMF) in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Reference to a study by L. Kam and colleagues published in a 2000 issue of "Inflammatory Bowel Disease" journal; Clinical information on...

  • Centocor/Johnson & Johnson: SONIC trial results support Remicade.  // PharmaWatch: Monthly Review;Dec2008, Vol. 7 Issue 12, p19 

    The article reports on the result of the clinical study of SONIC which demonstrates that Remicade is more effective than azathioprine monotherapy. The study further reveals that Remicade is significantly more effective than azathioprine monotherapy at inducing steroid-free remission and promotes...

  • UCB reports long-term benefits of Cimzia on Crohn's disease.  // PharmaWatch: Biotechnology;Jul2007, Vol. 6 Issue 7, p6 

    The article reports on the results of PRECiSE 3 study for UCB SA's Cimzia drug. The Belgium-based biopharmaceutical firm has presented new data of its study that demonstrates long-term response and remission in Crohn's disease patients treated with its experimental Cimzia drug. The primary...

  • Natalizumab gets an encore in Crohn's disease.  // PharmacoEconomics & Outcomes News;6/13/2009, Issue 580, p10 

    The article highlights the results of the ENCORE and ENACT-2 trials which examined the influence of natalizumab on the quality of life (QOL) of patients with Crohn's disease. ENCORE is an induction trial that compared natalizumab with placebo in patients who had failed anti-tumor necrosis factor...

  • Phase II/III.  // Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p16 

    Provides information related to latest phase II/III clinical trials. Initiation of a trial for an inhalable form of treprostinil for pulmonary hypertension by Lung Rx; Efficacy of Fibrillex at improving symptoms of Amylois A Amyloidosis, based on Neurochem Inc.'s trial.

  • Other trials.  // Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p18 

    Provides information related to recent clinical trials in the U.S. Initiation of trials for a tuberculosis drug from the Global Alliance for TB Drug Development; Benefit of endovascular aneurysm repair for low-risk patients; Recommendation by the Food and Drug Administration for Merck & Co. Inc....

  • Treatment of Gastric Ulcer. Juhl, Erik; Tygstrup, Niels; Christensen, Erik // American Journal of Gastroenterology;Mar1978 Part 1, Vol. 69 Issue 3, p272 

    Twenty-nine randomized clinical trials (RCTs) from the decade 1964-74 evaluating treatments of gastric ulcer have been analyzed. None of them fulfilled all criteria for an ideal RCT. The most frequent shortcomings were: short treatment or follow-up periods, incomplete description of the patients...

  • Comparative Study on the Bioequivalence of Two Different Gabapentin Formulations: A randomised, two-period, two-sequence, crossover clinical trial in healthy volunteers. Almeida, Susana; Filipe, Augusto; Almeida, Ana; Antonijoan, Rosa; GarcĂ­a-Gea, Consuelo; Gich, Ignasi; Barbanoj, Manuel; Caturla, Maria Cruz // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Feb2006, Vol. 56 Issue 2, p59 

    The bioequivalence of two capsule formulations containing 400 mg gabapentin (CAS 60142-96-3) was assessed in 24 healthy volunteers in an open, randomised, crossover, 2 periods x 2 sequences, with a minimum washout period of 7 days, single-dose study. Plasma samples were obtained at fixed time...

  • Ann Arbor biotech testing osteoporosis drug. Henderson, Tom // Crain's Detroit Business;3/10/2008, Vol. 24 Issue 10, p25 

    The article offers information regarding the drug trials of VEL0230, being conducted by Velcura Therapeutics Inc. It states that Velcura, an Ann Arbor, Michigan-based biotech heavily funded by federal and state grants since it was founded in 2001, has begun clinical trials of a new drug to fight...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics